Asset
ALENIGLIPRON
STRUCTURE THERAPEUTICS INC. AMERICAN DEPOSITARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07654374 | phase3 | recruiting | 2026-07-17 | 2028-09-01 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) |
| NCT05893043 | phase1 | completed | 2023-04-24 | 2023-06-28 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants |
| NCT06139055 | phase1 | unknown | 2023-10-02 | 2024-03-01 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants |
| NCT07400588 | phase2 | active_not_recruiting | 2025-12-01 | 2026-09-01 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Aleniglipron Phase 2 in Type 2 Diabetes Mellitus |
| NCT07654361 | phase3 | recruiting | 2026-07-13 | 2028-09-01 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) |
FDA applications (0)
This company has no applications containing this asset.